Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers
2 Regorafenib/Nivolumab Combo to Be Studied in Phase III Trial of Patients With MSS mCRC
3 Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
4 Regorafenib/Nivolumab Shows Modest Activity in MMR Proficient Advanced Refractory CRC
5 Bayer, BMS, Ono Pharma enter into clinical collaboration for colorectal cancer
6 Novel Combinations Dominate Later-Line Metastatic CRC Treatment Landscape
7 The Expanding Continuum of Care in Metastatic Colorectal Cancer
8 Bayer Data at ASCO 2019 Highlights Commitment to Evolving the Cancer Treatment Paradigm
9 Regorafenib/Nivolumab Combo to Be Explored in Phase III MSS CRC Trial
10 Bayer 2019: Fighting back – PharmaLive
11 Bristol-Myers Squibb 2019: More of everything – PharmaLive